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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the eGicacy and safety of interventions for managing abdominal pain in ulcerative colitis.
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B A C K G R O U N D
Description of the condition
Ulcerative colitis (UC) is a chronic inflammation of the colon
characterised by periods of relapse and remission (Ordas 2012).
It starts in the rectum and extends throughout the colon. UC and
Crohn’s disease (CD) are the two most common inflammatory
bowel diseases (IBD). However, UC tends to be more common than
CD, with an estimated prevalence of 90 to 505 cases per 100,000
people in North American and northern Europe (Conrad 2014).
Whilst prevalence has been historically higher in Western countries,
its incidence in industrialised parts of Asia and Latin America is
on the rise. The cause of UC is not known but is believed to be
associated with certain genetic and environmental factors. There is
a higher risk in Ashkenazi Jews, people with a family history of the
disease and those who live in Western countries (da Silva 2014).
Some of the symptoms of active UC include abdominal pain,
bloody stools and diarrhoea. These symptoms can be managed
using medical interventions such as 5-aminosalicylates, oral
corticosteroids, azathioprine or mecarptopurine (Iskandar 2015;
Iheozor-Ejiofor 2019) and by surgery in around 20 to 30% of
suGerers who do not successfully attain remission with drugs
(Ordas 2012). However, studies have shown that abdominal pain
persists in up to one third of UC patients in remission (Coates 2013).
This has been attributed to the coexistence of functional bowel
disorders such as IBS (irritable bowel syndrome). It is postulated
that as the symptoms of IBS and IBD share common underlying
psychological (for example anxiety and depression) and clinical
factors (for example colonic inflammation), an overlap of these
factors may trigger a myriad of events which result in persistent
pain in suGerers (Deberry 2014).
Description of the intervention
Pharmacological interventions
IBD medication can reduce inflammation and associated pain
by inducing remission. Where pain persists in the absence of
inflammation, it can be managed with pain-relieving medication
such as antispasmodics, non-steroidal anti-inflammatory drugs
(NSAID), cyclooxygenate-2 inhibitors (COX-2) and narcotics (Srinath
2012). Short-term use is advised due to the potential adverse eGects
of some of these drugs, .
Antispasmodics are a heterogenous group of drugs which can
relax intestinal muscles. Hyoscyamine and dicycloamine are the
most common antispasmodics that are used in IBD. NSAIDs are a
group of non-chemically related compounds which have analgesic
eGects. They reduce inflammation by inhibiting the production
of prostaglandins (Cavkaytar 2019). Examples include ibuprofen,
sulphasalazine, indomethacin and paracetamol. Some of these
drugs are available as over-the counter drugs. Narcotics are
psychoactive compounds with sleep-inducing properties such as
opiates and opioids, morphine, codeine, etc. Even though narcotics
have historically been viewed in a negative light, observational
studies indicate that they are commonly used not only for adults
but also children with IBD (Buckley 2013; Buckley 2015). Finally,
neuromodulators have been used in functional abdominal pain
syndromes and as such for abdominal pain in inflammatory bowel
disease (Mikocka-Walus 2020).
Non-pharmacological interventions
Non-pharmacological interventions used in managing abdominal
pain may include psychological interventions, lifestyle
advice, dietary interventions and alternative medicine. These
interventions are generally considered less invasive and may be
used as adjuvant treatment.
Psychological therapies are based on theories of human behaviour.
Cognitive behavioural therapy, stress management, and coping
skills training are the most common psychological interventions
used. These are an interesting set of therapies as the specific
interventions delivered can be very heterogenous and as such it is
key to consider the specific evidence and conceptual alignment of
the approach delivered to understand 'what' the therapy was, as
well as 'whether' it is eGective.
Dietary factors include alcohol elimination and the use of
supplements with prebiotic properties. Dietary factors have been
considered, with some evidence of impact (Norton 2017). There
is also interest in the use of probiotics for functional abdominal
pain syndromes, given their impact on the gut microbiome and the
reduction in inflammatory processes they may produce (Iheozor-
Ejiofor 2019).
Alternative medicine such as acupuncture and TENS, which have
been used with other conditions such as IBS, are being more
frequently used in IBD patients albeit with limited evidence (Srinath
2012). Acupuncture is a complementary therapy which is generally
used for pain unresponsive to standard therapy (Wilkinson 2007).
There are various techniques used in acupuncture such as basic
needling, laser acupuncture, and electroacupuncture.
How the intervention might work
The cause of the abdominal pain could require a targeted approach.
Pharmacological interventions
Antispasmodics oPen have mixed mechanisms of action, but
generally they tend to suppress intestinal spasms resulting from
inflammation or obstruction (Srinath 2012). Pharmacological
interventions may have associated adverse eGects. For example,
it is widely known that NSAIDs may increase the risk of disease
flare-up or exacerbation in IBD patients (Klein 2010). In addition
to oGering short-term relief, there seem to be concerns among
IBD suGerers about the stigma of addiction associated with
the use of opioids.The use of psychoactive drugs can also lead
to heavy dependence on them and a higher risk of mortality
(Coates 2013). In IBD patients, tapering oG narcotics could trigger
withdrawal symptoms which mimic IBD symptoms (Pauly 2017),
thus complicating further treatment. Therefore, long-term use for
IBD pain relief is not recommended.
Non-pharmacological interventions
Pain resulting from strictures can be eliminated by the introduction
of foods which can pass through with ease thereby preventing
intestinal pain (Srinath 2012). It has been postulated that recurrent
pain tends to lead to coping behaviours which worsen the
experience of pain. Psychological techniques such as cognitive
behavioural therapy work by targeting and stopping these negative
coping mechanisms that aGect how people deal with pain (Norton
2017). The mechanism of action of alternative and complementary
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therapies in itself is highly complex, but they are common use in
wider society and in turn are used by suGerers of UC.
Why it is important to do this review
Abdominal pain is a major driver for the use of healthcare facilities
in IBD suGerers. For about 70% of people with IBD, it is the main
reason for seeking medical attention. This puts a financial strain
on healthcare systems amounting to billions every year (Ghosh
2015). For the patient, it can lead to psychological problems, loss
of earnings and a general decline in quality of life. Therefore,
eGective pain management is vital. Pain management has been
highlighted as a priority topic for research by IBD patient groups
and charities but is currently not covered in the National Institute
for Health and Care Excellence (NICE) or European Crohn's and
Colitis Organisation (ECCO) guidelines (NICE 2019; ECCO 2010).
Whilst several non-Cochrane systematic reviews have assessed
interventions for pain management in IBD, there is currently none
which has assessed the eGicacy and safety of these interventions
specifically in UC. Even though this review covers interventions that
have been previously assessed in previously published Cochrane
systematic reviews (Iheozor-Ejiofor 2019; Limetkai 2019; Timmer
2011; Kafil 2018), the focus is only on studies that have been
conducted for the purpose of providing relief for abdominal pain.
O B J E C T I V E S
To assess the eGicacy and safety of interventions for managing
abdominal pain in ulcerative colitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published, unpublished and ongoing randomised trials that
compare interventions for the management of abdominal pain
with other active interventions or standard therapy, placebo or
no therapy. We will exclude studies that do not report on any
abdominal pain outcomes.
Induction or maintenance studies for UC that impact abdominal
pain as a proxy of disease state will not be considered. Similarly,
studies considering other pain in IBD, such as pain associated with
extra-manifestations will not be considered.
Studies including patients with both UC and CD will only be
included if the data for UC patients can be disaggregated.
Types of participants
People with UC who are experiencing abdominal pain.
Types of interventions
• Pharmacological treatments (e.g. antispasmodics,
antidepressants, laxatives, antidiarrhoeal agents, antibiotics,
analgesics, anti-reflux agents, antiemetic agents, antimigraine
agents, antihistaminic agents, serotonergic agents and
psychoactive drugs)
• Behaviour therapy (e.g. cognitive-behavioral therapy,
hypnotherapy)
• Lifestyle advice (e.g. advice on physical activity including
exercise)
• Dietary interventions (e.g. FODMAP, additional fibre intake,
decrease in gas producing foods, extra fluid intake, lactulose- /
gluten- / histamine-free diet)
• Prebiotics and probiotics
• Alternative medicines (e.g. acupuncture, homeopathy, body-
oriented therapy, musculoskeletal therapy (osteopathy/
chiropractic), yoga)
Types of outcome measures
Primary outcomes
• Treatment success as defined by the author
• Abdominal pain frequency or change in frequency of pain
• Abdominal pain intensity or change in pain intensity using any
validated scale
• Withdrawal due adverse events
Secondary outcomes
• Anxiety/depression
• Quality of life, using validated measures.
• Adverse events
• Serious adverse events
Timing of outcome measurement
Where outcomes are measured at multiple time points, they will be
subgrouped into three time periods: short-term (within 1 month of
the intervention), medium-term (<1 month to 6 months) and long-
term (more than 6 months).
Search methods for identification of studies
Electronic searches
We will search the following sources from the inception of each
database to the date of search and will place no restrictions on the
language of publication:
• Cochrane Central Register of Controlled Trials (CENTRAL) via the
Cochrane Register of Studies Online (CRSO)
• MEDLINE (Ovid MEDLINE ALL from 1946)
• PsycINFO via Ovid
• CINAHL via EBSCO (Cumulative Index to Nursing and Allied
Health Literature)
• AMED (Allied and Complementary Medicine database) via Ovid
• ClinicalTrials.gov (www.clinicaltrials.gov)
• World Health Organization International Clinical Trials Registry
Platform (ICTRP) (www.who.int/trialsearch/)
For detailed search strategies, see Appendix 1.
Searching other resources
As complementary search methods, we will carefully check relevant
systematic reviews for studies for potential inclusion in our review.
In addition, we will scrutinize the references of included studies in
our review. We will seek unpublished trials by contacting experts
in the field and we will scan the Internet and abstracts submitted
to major international congresses from the three years prior to the
search to capture any studies presented but not yet published in
full.
Interventions for the management of abdominal pain in ulcerative colitis (Protocol)
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We will attempt to obtain translations of papers when necessary.
Data collection and analysis
We will carry out data collection and analysis according to the
methods recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Selection of studies
Two review authors will independently screen the titles and
abstracts identified from the literature search. We will discard
studies which do not meet the inclusion criteria. We will then
obtain the full report of studies which appear to meet our inclusion
criteria or for which there is insuGicient information to make a final
decision. When these articles are obtained, two review authors will
independently assess them to establish whether the studies meet
the inclusion criteria. We will resolve disagreements by discussion,
with a third review author consulted if resolution is not possible.
We will enter studies rejected at this or subsequent stages in the
'Characteristics of excluded studies' tables and record the main
reason for exclusion.
Data extraction and management
Two authors will carry out data extraction independently using
piloted data extraction forms. We will extract relevant data from
full-text articles that meet the inclusion criteria. If reported,
information will be collected on:
• Trial setting: country and number of trial centres
• Methods: study design, total study duration and date
• Participant characteristics: age, socio-demographics, ethnicity,
diagnostic criteria and total number
• Eligibility criteria: inclusion and exclusion criteria
• Intervention and comparator
• Outcomes: outcome definition, unit of measurement and time
of collection
• Results: number of participants allocated to each group, missing
participants, sample size
• Funding source
Assessment of risk of bias in included studies
During data extraction, two review authors will independently
assess all studies meeting the inclusion criteria for their risk of bias
using criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The domains that will be
assessed are as follows:
• Sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel (performance bias)
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Other bias
We will judge the studies to be at either low, high or unclear risk of
bias for each domain assessed, based on the guidance in Higgins
2011.
APer data extraction, the two review authors will compare the
extracted data to discuss and resolve discrepancies before the data
are transferred into the Characteristics of included studies table.
For cluster RCTs, we intend to judge risk of bias as prescribed in
Section 16.3.2 of the Cochrane Handbook.
Measures of treatment e9ect
For the dichotomous outcomes, we will express treatment eGect
as risk ratios (RR) with corresponding 95% CI. For continuous
outcomes, we will express the treatment eGect as mean diGerence
(MD) with 95% CI. However, if the studies assess the same
continuous outcome in diGerent ways, we will estimate the
treatment eGect using the standardised mean diGerence (SMD).
We will present SMDs as standard deviation units and interpret as
follows: 0.2 represents a small eIect, 0.5 a moderate eIect and 0.8 a
large eIect (Cohen 1988).
Unit of analysis issues
The participant will be the unit of analysis. For studies comparing
more than two intervention groups, we will make multiple pair-
wise comparisons between all possible pairs of intervention
groups. To avoid double counts, we intend to divide out
shared intervention groups evenly among the comparisons. For
dichotomous outcomes, we plan to divide up both the number of
events and the total number of patients. For continuous outcomes,
we will only divide up the total number of participants and leave
the means and standard deviations unchanged. Cross-over studies
will only be included if data are separately reported before and
aRer cross-over. We do not anticipate any cluster RCTs, however,
study data will only be used if the authors have used appropriate
statistical methods in taking clustering eIect into account. We will
also exclude cluster RCTs in a sensitivity analysis to assess their
impact on the results.
Dealing with missing data
We aim to contact authors where there is missing data or studies
have not reported data in suGicient detail. We will attempt to
estimate missing standard deviations using relevant statistical
tools and calculators if studies report standard errors. Studies
which fail to report measures of variance will be judged as being at
high risk of selective reporting bias.
Assessment of heterogeneity
We plan to scrutinise studies to ensure that they are clinically
homogenous in terms of participants, intervention, comparator
and outcome. To test for statistical heterogeneity, we will use a chi2
test. A P-value of less than 0.1 will give an indication of the presence
of heterogeneity. Inconsistency will be quantified and represented
by the I2 statistic. The thresholds are interpreted as follows (Higgins
2011):
0% to 40%: might not be important
30% to 60%: may represent moderate heterogeneity
50% to 90%; may represent substantial heterogeneity
75% to 100%: considerable heterogeneity
Interventions for the management of abdominal pain in ulcerative colitis (Protocol)
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Assessment of reporting biases
Most reporting biases will be minimised by using an inclusive
search strategy. We will investigate publication bias using a funnel
plot if there are 10 or more studies. The magnitude of publication
bias will be determined by visual inspection of the asymmetry of
the funnel plot. In addition, we will test funnel plot asymmetry
by performing a linear regression of intervention eGect estimate
against its standard error, weighted by the inverse of the variance
of the intervention eGect estimate (Egger 1997).
Data synthesis
To summarise the study characteristics, we intend to conduct
a narrative synthesis of all the included studies. We will then
carry out a meta-analysis if there are two more studies that
have assessed similar populations, interventions and outcomes.
Studies from paediatric population, adult population and diIerent
subintervention types will be analysed separately. We will use
Review Manager 5.3 (RevMan 2014). Study data will be synthesised
using the random-eGects model. We will combine eGect estimates
of studies which report data in a similar way, in the meta-
analysis. We will pool RRs for dichotomous outcomes and MDs for
continuous outcomes alongside 95% confidence intervals. Where
we are unable to carry out a meta-analysis (e.g. due to lack of
uniformity in data reporting), we will present a narrative summary
of the included studies.
Subgroup analysis and investigation of heterogeneity
If heterogeneity is detected, we will investigate possible causes and
address them using methods described in Higgins 2011. We will
also undertake subgroup analyses of potential eGect modifiers if
there are 10 studies or more. We have identified several potential
modifiers of eGect:
• Disease activity (active versus inactive disease)
• Pain location
• Disease location
It is recognised that the nature of the studies likely to be included in
this review may be capricious and heterogenous in a number of key
clinical and methodological ways that cannot be fully predicted. If
such factors are identified and become relevant to ensure integrity
of the analysis, modifications to this list may be needed. These will
be fully reported by the authors.
Sensitivity analysis
Where possible, we plan to undertake a sensitivity analysis on the
primary outcome of 'treatment success', to assess whether the
findings of the review are robust to the decisions made during the
review process. In particular, we intend to exclude studies at high
or unclear risk of bias due to allocation bias and performance bias,
from analyses that have a mix of studies with diIerent risk of bias
judgements. Where data analyses include studies with reported
and estimated SDs, plan to exclude those with estimated standard
deviations to assess whether this aIects the findings of the review.
We will investigate whether the choice of model (fixed versus
random) impacts the results to explore heterogeneity.
Summary of findings and assessment of the certainty of the
evidence
We will present the main results in a 'Summary of findings'
table. Each comparison and primary outcome will be exported
to GRADEprofiler soPware (developed by the Grades of
Recommendations, Assessment, Development and Evaluation
(GRADE) Working Group) for quality assessment (GRADE 2015). Data
permitting, we intend to present five summary of findings tables
in the following hierarchy: comparisons involving pain-relieving
drugs, behavioural therapy, lifestyle advice, dietary interventions,
prebiotics and probiotics. We will include all four primary
outcomes. We will apply GRADE to any additional comparisons
and present these in additional tables. Based on risk of bias,
inconsistency, imprecision, indirectness and publication bias, we
will rate the quality of the evidence for each outcome as high,
moderate, low or very low. These ratings have been defined as
follows:
• High: further research is very unlikely to change our confidence
in the estimate of eGect
• Moderate: further research is likely to have an important impact
on our confidence in the estimate of eGect and may change the
estimate
• Low: further research is very likely to have an important impact
on our confidence in the estimate of eGect and is likely to change
the estimate
• Very low: any estimate of eGect is very uncertain
We will justify all decisions to downgrade the quality of studies
using footnotes and we will make comments to aid reader's
understanding of the review where necessary.
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane CCTR, CDSR search strategy (via Ovid)
1. exp Pain/
2. pain*.tw,kw.
3. ((abdominal or abdomen) and (discomfort* or ache* or aching or migraine* or fibromyalgia* or neuralgia* or colic*)).tw,kw.
4. or/1-3
5. exp Colitis, Ulcerative/
6. Inflammatory Bowel Diseases/
7. (ulcer* adj5 colitis).tw,kw.
8. inflammatory bowel disease*.tw,kw.
9. (colitis gravis or proctocolitis or procto colitis or mucosal colitis or colorectitis or UC).tw,kw.
10.or/5-9
11.4 and 10
2 MEDLINE search strategy (via Ovid)
1. exp Pain/
2. pain*.tw,kw.
3. ((abdominal or abdomen) and (discomfort* or ache* or aching or migraine* or fibromyalgia* or neuralgia* or colic*)).tw,kw.
4. or/1-3
5. exp Colitis, Ulcerative/
6. Inflammatory Bowel Diseases/
7. (ulcer* adj5 colitis).tw,kw.
8. inflammatory bowel disease*.tw,kw.
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21.exp animals/ not humans/
22.20 not 21
23.11 and 22
24.cochrane database of systematic reviews.jn. or search*.tw. or meta analysis.pt. or medline.tw. or systematic review.tw.
25.11 and 24
26.23 or 25
(lines 12-22: [Cochrane Handbook RCT filter - sensitivity max version]
line 24:[Wong 2006 – systematic reviews filter – specificity maximizing version])






6. ((abdominal or abdomen) and (discomfort* or ache* or aching or migraine* or fibromyalgia* or neuralgia* or colic*)).tw.
7. or/1-6
8. exp Ulcerative Colitis/
9. (ulcer* adj5 colitis).tw.
10.inflammatory bowel disease*.tw.
11.(colitis gravis or proctocolitis or procto colitis or mucosal colitis or colorectitis or UC).tw.
12.or/8-11
13.7 and 12
14.(control* or random*).tw. or exp Treatment/
15.13 and 14
4 CINAHL search strategy (EBSCO)
S1. MH "Pain+"
S2.TI pain* OR AB pain*
S3. TI ( (abdominal or abdomen) and (discomfort* or ache* or aching or migraine* or fibromyalgia* or neuralgia* or colic*) ) OR AB
( (abdominal or abdomen) and (discomfort* or ache* or aching or migraine* or fibromyalgia* or neuralgia* or colic*) )
S4. S1 OR S2 OR S3
S5. (MH "Colitis, Ulcerative")
S6. TI ( ulcer* and colitis ) OR AB ( ulcer* and colitis )
S7. TI inflammatory bowel disease* OR AB inflammatory bowel disease*
S8. TI ( colitis gravis or proctocolitis or procto colitis or mucosal colitis or colorectitis or UC ) OR AB ( colitis gravis or proctocolitis or procto
colitis or mucosal colitis or colorectitis or UC )
S9. S5 OR S6 OR S7 OR S8
S10. S4 AND S9
S11. MH "prognosis+" OR MH "study design+" OR random*
S12. S10 AND S11
(Line S11: [Wong 2006 "CINAHL therapy studies" filter – best sensitivity version])
5 AMED search strategy (via Ovid)
1. pain*.tw.
2. ((abdominal or abdomen) and (discomfort* or ache* or aching or migraine* or fibromyalgia* or neuralgia* or colic*)).tw.
3. or/1-2
4. (ulcer* adj5 colitis).tw.
5. inflammatory bowel disease*.tw.
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Cochrane Database of Systematic Reviews
6. (colitis gravis or proctocolitis or procto colitis or mucosal colitis or colorectitis or UC).tw.
7. or/4-6
8. 3 and 7
6 ClinicalTrials.gov search strategy (Adavnced Search)
Condition/ Disease: (ulcerative colitis OR inflammatory bowel disease OR colitis gravis OR proctocolitis OR procto colitis OR mucosal colitis
OR colorectitis)
Other terms: (pain OR pains OR ache* OR aching OR fibromyalgia* OR neuralgia* OR colic*)
Study Type: Interventional Studies
7 WHO ICTRP Search Portal search strategy (Standard search)
pain* AND ulcerative colitis OR
ache* AND ulcerative colitis OR
aching AND ulcerative colitis OR
colic* AND ulcerative colitis OR
pain* AND inflammatory bowel disease OR
ache* AND inflammatory bowel disease OR
aching AND inflammatory bowel disease OR
colic* AND inflammatory bowel disease OR
pain* AND proctocolitis OR
ache* AND proctocolitis OR
aching AND proctocolitis OR
colic* AND proctocolitis OR
pain* AND colorectitis OR
ache* AND colorectitis OR
aching AND colorectitis OR
colic* AND colorectitis
H I S T O R Y
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